Lupin launches insulin glargine in India

August 7, 2014 8:46 AM

Indian pharma company, Lupin Limited announced a strategic distribution agreement with LG Life Sciences of South Korea to launch Insulin Glargine, a novel insulin analogue under the brand name Basugine™.

According to the agreement, Lupin would be responsible for marketing and sales of Basugine™ in India.

The overall diabetes market size within the Indian pharmaceutical market stood at Rs. 6032 Crore growing at 18% (IMS MAT April 2014). The total insulin analogue market size is valued at Rs. 585 Crore with 3 year CAGR of 24%. The total glargine molecule market is Rs. 218.5 Crore with 3 year CAGR of 23%. Lupin ranks 2nd in the conventional insulin market and grew more than the market at 10.82% in April 2014 (IMSD MAT), while the market grew at 8%. Lupin is amongst the fastest growing players in the Oral Anti-Diabetes Drugs market and also in the insulin segment.

Insulin Glargine is indicated for once – daily subcutaneous administration for the treatment of adult patients with type 1 diabetes mellitus or in type 2 diabetes mellitus; patients who need basal insulin (long acting) for controlling hyperglycemia. The primary activity of insulin, including Insulin Glargine, is the regulation of glucose metabolism. Insulin and its analogues lower blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production.

Announcing the launch, Mr. Shakti Chakraborty, Group President, India Region Formulations, Lupin said– “I believe that our entry into the insulin analogue market with launch of Basugine is a step in the right direction. Lupin’s foray in this segment will help us furtherstrengthen our Diabetes portfolio enabling us to grow deeperinto the Diabetes segment and will fuel our growth in the years to come.”


Source: Lupin press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!